Back to search results

Long-Term Follow-up for Imdusiran in Chronic Hepatitis B

This study is a long-term follow-up for people with chronic hepatitis B (CHB) who previously received a treatment called imdusiran in another clinical trial. You can join if you stopped your usual hepatitis B medication (NA therapy) during that earlier trial and are still off it. The main goal is to see how long the effects of imdusiran last on your hepatitis B over time, up to 96 weeks. This study is observational, meaning there are no new treatments given, only monitoring. The study aims to enroll 50 participants, but its current status is unclear.

Study design
This is an observational study, meaning no new treatments are given, and it plans to enroll 50 participants.
What's involved
You would have blood samples taken, your current medications reviewed, and any side effects reported. Participation will last for approximately 2 years.
Compensation
Not stated in the trial record.
Follow-up
The study will evaluate the durability of imdusiran's effect for up to 96 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06277037

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Recruiting
Not specifiedAges 20–70Observational
Arbutus Biopharma Corporation
~50 participants
Updated 2024-11-27 on ClinicalTrials.gov
What's tested:Non-interventional

At a glance

Recruiting sites
12 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the durability of effect of imdusiran on HBV parameters
Measured over Up to 96 weeks
+2 more outcomes measured

Conditions

Long Term Follow-up

Explore related trials

Chronic Hepatitis B

Where it's being run

18 sites across 11 states
Taiwan6
United Kingdom3
California1
Florida1
New Jersey1
Victoria1
Australia1
New Territories1

Who to contact

Michael Child
[email protected]
267-332-6213
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have participated in a prior imdusiran clinical trial,
Have discontinued NA therapy in that trial and remain off NA therapy,
Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study.
Have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements.

Exclusion

Not applicable

What this trial measures

  • To evaluate the durability of effect of imdusiran on HBV parametersUp to 96 weeks

    Change from pre-"parent" study baseline and over time in HBsAg, HBV DNA, and hepatitis B surface antibody (HBsAb) at each timepoint.

  • To evaluate the durability of effect of imdusiran on HBV parametersUp to 96 weeks

    Proportion of subjects who remain off NA therapy and duration off NA therapy, if applicable

  • To evaluate the durability of effect of imdusiran on HBV parametersUp to 96 weeks

    Proportion of subjects who restart NA therapy, if applicable